RECRUITING

C-Protein in Fatigue and Aging

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is investigating changes to the proteins in skeletal muscle that contribute to reduced muscle size and muscle function that occurs with aging.

Official Title

Skeletal Muscle Myosin Binding Protein C in Fatigue and Aging

Quick Facts

Study Start:2017-11-06

Study Completion:2025-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05926219

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Adults between the ages 18-35 or 65-80 years * Healthy by self-report * Willing to participate in all aspects of the study design including muscle biopsy, unilateral exercise, and physical activity monitoring * Fluent in English (due to lack of translation services, it is not practical to conduct the study using a language other than English).	* Orthopaedic limitation (severe knee osteoarthritis, prior joint replacement, etc.). * Volunteer has dementia or related mental issues that potentially put the subject at risk as determined by prior diagnosis. * Volunteer has known untreated endocrine disease (hypo/hyper thyroidism, Addison's Disease or Cushing's syndrome, etc.) * Volunteer has untreated/poorly-controlled hypertension (stage 2, per American College of Cardiology \[\>140/90 mmHg\]). * Volunteer has significant heart, liver, kidney or respiratory disease. * Volunteer has diabetes (insulin dependent or non-insulin dependent). * Volunteer has known coagulopathies. * Volunteer has taken anabolic steroids in the prior six months. * Volunteer has received treatment for cancer (other than effective Mohs Surgery for successful removal of basal cell or squamous cell carcinomas) * Unexpected weight loss \>5kg is last 12 months * Volunteer is an active smoker or quit within the last year. * Volunteer has known current alcohol or drug use disorder (AUD; defined as binge drinking of \>4 days in the last month. Binge drinking is \>5 drinks for men and \>4 drinks for women, per occasion). Or, if a volunteer reports drinking in excess of "low risk" per NIAAA (\>7 drinks/week for men and \>3 drinks/day for women and \>14 drinks/week and \>4 drinks/day). * Volunteer has a diagnosed neuromuscular disorder. * Volunteer has allergy to lidocaine.

Inclusion Criteria

Exclusion Criteria

* Adults between the ages 18-35 or 65-80 years
* Healthy by self-report
* Willing to participate in all aspects of the study design including muscle biopsy, unilateral exercise, and physical activity monitoring
* Fluent in English (due to lack of translation services, it is not practical to conduct the study using a language other than English).

* Orthopaedic limitation (severe knee osteoarthritis, prior joint replacement, etc.).
* Volunteer has dementia or related mental issues that potentially put the subject at risk as determined by prior diagnosis.
* Volunteer has known untreated endocrine disease (hypo/hyper thyroidism, Addison's Disease or Cushing's syndrome, etc.)
* Volunteer has untreated/poorly-controlled hypertension (stage 2, per American College of Cardiology \[\>140/90 mmHg\]).
* Volunteer has significant heart, liver, kidney or respiratory disease.
* Volunteer has diabetes (insulin dependent or non-insulin dependent).
* Volunteer has known coagulopathies.
* Volunteer has taken anabolic steroids in the prior six months.
* Volunteer has received treatment for cancer (other than effective Mohs Surgery for successful removal of basal cell or squamous cell carcinomas)
* Unexpected weight loss \>5kg is last 12 months
* Volunteer is an active smoker or quit within the last year.
* Volunteer has known current alcohol or drug use disorder (AUD; defined as binge drinking of \>4 days in the last month. Binge drinking is \>5 drinks for men and \>4 drinks for women, per occasion). Or, if a volunteer reports drinking in excess of "low risk" per NIAAA (\>7 drinks/week for men and \>3 drinks/day for women and \>14 drinks/week and \>4 drinks/day).
* Volunteer has a diagnosed neuromuscular disorder.
* Volunteer has allergy to lidocaine.

Contacts and Locations

Study Contact

Damien M Callahan, Ph.D.

CONTACT

541-346-5040

damienc@uoregon.edu

Karen Wiedenfeld Needham, BS

CONTACT

541-346-7610

needham@uoregon.edu

Principal Investigator

Damien M Callahan, Ph.D.

PRINCIPAL_INVESTIGATOR

University of Oregon

Study Locations (Sites)

University of Oregon

Eugene, Oregon, 97403

United States

Collaborators and Investigators

Sponsor: University of Oregon

Damien M Callahan, Ph.D., PRINCIPAL_INVESTIGATOR, University of Oregon

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-11-06

Study Completion Date2025-01

Study Record Updates